Brivanib (alaninate)

Overview

Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC 50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1 , but more than 240-fold against PDGFRβ .

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-10336
• CAS No.: 649735-63-7
• Molecular Formula: C22H24FN5O4
• Molecular Weight: 441.46
• Purity: 99.45%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.08 mg/mL (4.71 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source